Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)

Schadendorf, D. and Hassel, J. C. and Fluck, M. and Eigentler, T. and Loquai, C. and Berneburg, M. and Gutzmer, R. and Meier, F. and Mohr, P. and Hauschild, A. and Becker, J. C. and Menzer, C. and Kiecker, F. and Dippel, E. and Simon, J-C. and Conrad, B. and Garbe, C. and Koerner, S. and Livingstone, E. and Zimmer, L. (2019) Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). ANNALS OF ONCOLOGY, 30 (Suppl5). pp. 903-904. ISSN 0923-7534, 1569-8041

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Dermatologie und Venerologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 24 Mar 2020 12:13
Last Modified: 24 Mar 2020 12:13
URI: https://pred.uni-regensburg.de/id/eprint/26089

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.